

2014 Publications

O'Hurley G, Prencipe M, Lundon D, O'Neill A, Boyce S, O'Grady A, Gallagher WM, Morrissey C, Kay EW, Watson RW. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases. *Prostate*. 2014 Feb;74(3):306-13. doi: 10.1002/pros.22752. PubMed [PMID: 24249383](#)

Duffy MJ, Crown J. Precision treatment for cancer: Role of prognostic and predictive markers. *Crit Rev Clin Lab Sci*. 2014 Feb;51(1):30-45. doi: 10.3109/10408363.2013.865700. Epub 2014 Jan 16. [PubMed PMID: 24432844](#)

2: Candon D, Healy J, Crown J. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer. *Acta Oncol*. 2014 Feb;53(2):201-8. doi: 10.3109/0284186X.2013.840740. Epub 2013 Oct 14. [PubMed PMID: 24125103](#)

2013 Publications

Hill AF, Pegtel DM, Lambertz U, Leonardi T, O'Driscoll L, Pluchino S, Ter-Ovanesyan D, Nolte-t Hoen EN. ISEV position paper: extracellular vesicle RNA analysis and bioinformatics. *J Extracell Vesicles*. 2013 Dec 23;2. doi: 10.3402/jev.v2i0.22859. eCollection 2013. [PubMed PMID: 24376909](#)

Mulrane L, McGee SF, Gallagher WM, O'Connor DP. miRNA dysregulation in breast cancer. *Cancer Res*. 2013 Nov 15;73(22):6554-62. doi: 10.1158/0008-5472.CAN-13-1841. Epub 2013 Nov 7. Review. [PubMed PMID: 24204025](#)

O'Hurley G, Daly E, O'Grady A, Cummins R, Quinn C, Flanagan L, Pierce A, Fan Y, Lynn MA, Rafferty M, Fitzgerald D, Pontén F, Duffy MJ, Jirström K, Kay EW, Gallagher WM. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. *Histopathology*. 2013 Oct 19. doi: 10.1111/his.12313. [Epub ahead of print] PubMed [PMID: 24138071](#)

Canonici A, Gijssen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. *Oncotarget*. 2013 Oct;4(10):1592-605. PubMed [PMID: 24009064](#)

O'Neill F, Madden SF, Clynes M, Crown J, Doolan P, Aherne ST, O'Connor R. A gene expression profile indicative of early stage HER2 targeted therapy response. *Mol Cancer*. 2013 Jul 1;12:69. doi: 10.1186/1476-4598-12-69. PubMed [PMID: 23816254](#)

Madden SF, Clarke C, Aherne ST, Gaule P, O'Donovan N, Crown J, Clynes M, Gallagher WM. BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. *Breast Cancer Res*. 2013 Jul 2;15(4):R52. [Epub ahead of print] PubMed [PMID: 23820017](#)

Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M. Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. *Carcinogenesis*. 2013 Jul 8. [Epub ahead of print] PubMed [PMID: 23740839](#).

Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. *Mol Oncol*. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31. PubMed [PMID: 23415752](#).

Myhre S, Lingjærde OC, Hennessy BT, Aure MR, Carey MS, Alsner J, Tramm T, Overgaard J, Mills GB, Børresen-Dale AL, Sørli T. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. *Mol Oncol*. 2013 Jun;7(3):704-18. doi: 10.1016/j.molonc.2013.02.018. Epub 2013 Mar 19. PubMed [PMID: 23562353](#)

Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. *Cancer Biol Ther*. 2013 Jun 1;14(6):537-45. doi: 10.4161/cbt.24349. PubMed [PMID: 23760496](#).

Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N. EGFR and HER2 inhibition in pancreatic cancer. *Invest New Drugs*. 2013 Jun;31(3):558-66. doi: 10.1007/s10637-012-9891-x. Epub 2012 Oct 18. PubMed [PMID: 23076814](#)

O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW, O'Driscoll L. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. *Eur J Cancer*. 2013 May;49(8):1845-59. doi: 10.1016/j.ejca.2013.01.017. Epub 2013 Feb 27. PubMed [PMID: 23453937](#).

Duffy MJ, Crown J. Companion biomarkers: paving the pathway to personalized treatment for cancer. *Clin Chem*. 2013 Oct;59(10):1447-56. doi: 10.1373/clinchem.2012.200477. Epub 2013 May 8. Review. PubMed [PMID: 23656699](#)

Prencipe M, Madden SF, O'Neill A, O'Hurley G, Culhane A, O'Connor D, Klocker H, Kay EW, Gallagher WM, Watson WR. Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target? *Prostate*. 2013 May;73(7):743-53. doi: 10.1002/pros.22618. Epub 2013 Jan 28. PubMed [PMID: 23359479](#).

Duffy MJ. The war on cancer: are we winning? *Tumour Biol*. 2013 Jun;34(3):1275-84. doi: 10.1007/s13277-013-0759-2. Epub 2013 Apr 9. Review. PubMed [PMID: 23568704](#)

O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM. Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. *BMC Cancer*. 2013 Apr 2;13:175. doi: 10.1186/1471-2407-13-175. PubMed [PMID: 23547718](#)

Vajda A, Marignol L, Barrett C, Madden SF, Lynch TH, Hollywood D, Perry AS. Gene expression analysis in prostate cancer: the importance of the endogenous control. *Prostate*. 2013 Mar;73(4):382-90. doi: 10.1002/pros.22578. Epub 2012 Aug 27. PubMed [PMID: 22926970](#).

Breslin S, O'Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. *Drug Discov Today*. 2013 Mar;18(5-6):240-9. doi: 10.1016/j.drudis.2012.10.003. Epub 2012 Oct 13. Review. [PubMed PMID: 23073387](#)

McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, Pierce A, McDermott EW, Crown J, O'Donovan N, Duffy MJ. ADAM-17: a novel therapeutic target for triple negative breast cancer. *Ann Oncol*. 2013 Feb;24(2):362-9. doi: 10.1093/annonc/mds279. Epub 2012 Sep 11. PubMed [PMID: 22967992](#)

2012 Publications

Brennan DJ, O'Connor DP, Laursen H, McGee SF, McCarthy S, Zagodzdon R, Rexhepaj E, Culhane AC, Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC, Crown JP, Jirström K, Gallagher WM. The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER α , and is an independent prognostic factor in node-negative breast cancer. *Oncogene*. 2012 Jul 26;31(30):3483-94. doi: 10.1038/onc.2011.519. Epub 2011 Dec 5. PubMed [PMID: 22139072](#).

Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V, Clynes M. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. *Int J Cancer*. 2012 Aug 15;131(4):911-23. doi: 10.1002/ijc.26462. Epub 2011 Nov 19. [PubMed PMID: 21953030](#).

O'Connell K, Prencipe M, O'Neill A, Corcoran C, Rani S, Henry M, Dowling P, Meleady P, O'Driscoll L, Watson W, O'Connor R. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. *Proteomics*. 2012 Jul;12(13):2115-26. doi: 10.1002/pmic.201100489. PubMed [PMID: 22623417](#).

Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. *Ann Oncol*. 2012 Jul;23(7):1788-95. Epub 2011 Nov 5. PubMed [PMID: 22056974](#).

O'Neill F, Madden SF, Aherne ST, Clynes M, Crown J, Doolan P, O'Connor R. Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines. *Mol Cancer*. 2012 Jun 18;11(1):41. [Epub ahead of print] PubMed [PMID: 22709873](#).

Zagodzdon AM, O'Leary P, Callanan JJ, Crown J, Gallagher WM, Zagodzdon R. Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. *BMC Cancer*. 2012 May 30;12:209. PubMed PMID: 22646761; PubMed Central [PMCID: PMC3411433](#).

Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L. MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target

involved in breast cancer tumorigenesis. *Int J Cancer*. 2012 May 1;130(9):1991-2002. doi: 10.1002/ijc.26200. Epub 2011 Aug 8. PubMed [PMID: 21618523](#).

Geiger T, Madden SF, Gallagher WM, Cox J, Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. *Cancer Res*. 2012 May 1;72(9):2428-39. Epub 2012 Mar 13. PubMed [PMID: 22414580](#).

Radziwon-Balicka A, Medina C, O'Driscoll L, Treumann A, Bazou D, Inkielewicz-Stepniak I, Radomski A, Jow H, Radomski MW. Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. *Br J Pharmacol*. 2012 Apr 17. doi: 10.1111/j.1476-5381.2012.01991.x. [Epub ahead of print] PubMed [PMID: 22506717](#).

Keenan J, Joyce H, Aherne S, O'Dea S, Doolan P, Lynch V, Clynes M. Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line. *Exp Cell Res*. 2012 Mar 10;318(5):593-602. Epub 2012 Jan 13. PubMed [PMID: 22281030](#).

O'Connor AE, Mc Gee MM, Likar Y, Ponomarev V, Callanan JJ, O'shea DF, Byrne AT, Gallagher WM. Mechanism of cell death mediated by a BF₂-chelated tetraaryl-azadipyromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo. *Int J Cancer*. 2012 Feb 1;130(3):705-15. doi: 10.1002/ijc.26073. Epub 2011 May 26. PubMed [PMID: 21413012](#).

2011 Publications

Dunne G, Breen L, Collins DM, Roche S, Clynes M, O'Connor R. Modulation of P-gp expression by lapatinib. *Invest New Drugs*. 2011 Dec;29(6):1284-93. doi: 10.1007/s10637-010-9482-7. Epub 2010 Jul 6. PubMed [PMID: 20607587](#)

Fox D, O'Connor R, Mallon P, McMahon G. Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma. *J Pharm Biomed Anal*. 2011 Dec 5;56(4):785-91. Epub 2011 Jul 30. PubMed [PMID: 21840662](#).

Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A, O'Donovan N, Crown J, Duffy MJ. Src: a potential target for the treatment of triple-negative breast cancer. *Ann Oncol*. 2011 Oct;22(10):2234-40. Epub 2011 Feb 28. PubMed [PMID: 21357651](#).

O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. *Mol Cancer*. 2011 Oct 7;10:126. PubMed [PMID: 21982118](#)

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011 Oct 6;365(14):1273-83. PubMed [PMID: 21991949](#)

Zagozdzon R, Gallagher WM, Crown J. Truncated HER2: implications for HER2-targeted therapeutics. *Drug Discov Today*. 2011 Sep;16(17-18):810-6. Epub 2011 Jun 16. Review. PubMed [PMID: 21704182](#).

Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? *Clin Proteomics*. 2011 Jun 9;8(1):9. PubMed PMID: 21906355; PubMed Central [PMCID: PMC3170276](#).

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhvani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. *Cancer Discov*. 2011 Jun;1(1):54-67. Epub 2011 Jun 1. PubMed [PMID: 22039576](#)

McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of S100 genes in breast cancer progression. *Tumour Biol*. 2011 Jun;32(3):441-50. Epub 2010 Dec 14. PubMed [PMID: 21153724](#).

Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: Where are we? *Int J Cancer*. 2012 May 14. doi: 10.1002/ijc.27632. [Epub ahead of print] PubMed [PMID: 22581656](#).

Duffy MJ, O'Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients. *Cancer Treat Rev*. 2011 Apr;37(2):151-9. doi: 10.1016/j.ctrv.2010.07.004. Epub 2010 Aug 3. Review. PubMed [PMID: 20685042](#)

van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. *Drug Discov Today*. 2011 Mar;16(5-6):219-28. Epub 2011 Jan 22. Review. PubMed [PMID: 21262381](#).

Brennan DJ, Laursen H, O'Connor DP, Borgquist S, Uhlen M, Gallagher WM, Pontén F, Millikan RC, Rydén L, Jirstrom K. Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. *Breast Cancer Res*. 2011 Jan 31;13(1):R12. PubMed [PMID: 21281480](#)

Sheridan H, Nestor C, O'Driscoll L, Hook I. Isolation, structure elucidation, and cytotoxic evaluation of furanonaphthoquinones from in vitro plantlets and cultures of *Streptocarpus dunnii*. *J Nat Prod*. 2011 Jan 28;74(1):82-5. Epub 2010 Dec 21. PubMed [PMID: 21174407](#).

Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, O'Donovan N. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. *Ann Oncol*. 2011 Jan;22(1):68-73. doi: 10.1093/annonc/mdq349. Epub 2010 Jul 20. PubMed [PMID: 20647220](#)

Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. *Clin Chem*. 2011 Jan;57(1):18-32. doi: 10.1373/clinchem.2010.150730. Epub 2010 Nov 8. Review. PubMed [PMID: 21059829](#)

Brougham DF, Ivanova G, Gottschalk M, Collins DM, Eustace AJ, O'Connor R, Havel J. Artificial neural networks for classification in metabolomic studies of whole cells using ¹H nuclear magnetic resonance. *J Biomed Biotechnol.* 2011;2011:158094. Epub 2010 Sep 15. PubMed [PMID: 20886062](#)

Rani S, O'Brien K, Kelleher FC, Corcoran C, Germano S, Radomski MW, Crown J, O'Driscoll L. Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling. *Methods Mol Biol.* 2011;784:181-95. doi: 10.1007/978-1-61779-289-2_13. PubMed [PMID: 21898221](#).

Friel AM, Crown J, O'Driscoll L. Analysis of gene expression as relevant to cancer cells and circulating tumour cells. *Methods Mol Biol.* 2011;784:55-75. doi: 10.1007/978-1-61779-289-2_5. PubMed [PMID: 21898213](#).

Gately K, Kerr K, O'Byrne K. Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis. *Methods Mol Biol.* 2011;784:139-53. doi: 10.1007/978-1-61779-289-2_10. PubMed [PMID: 21898218](#).

Germano S, O'Driscoll L. Western blotting analysis as a tool to study receptor tyrosine kinases. *Methods Mol Biol.* 2011;784:109-21. doi: 10.1007/978-1-61779-289-2_8. PubMed [PMID: 21898216](#).

2010 Publications

Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. *BMC Cancer.* 2010 Nov 23;10:639. PubMed PMID: 21092276; PubMed Central [PMCID: PMC2999619](#).

Sheikh R, Walsh N, Clynes M, O'Connor R, McDermott R. Challenges of drug resistance in the management of pancreatic cancer. *Expert Rev Anticancer Ther.* 2010 Oct;10(10):1647-61. Review. PubMed [PMID: 20942635](#).

Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. *Nat Rev Cancer* 2010; 10(9):605-17. [PMID: 20720569](#)

Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, Clynes M, O'Connor R. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. *Invest new Drugs.* 2010 28(4):433-44. [PMID: 19499189](#)

Friel AM, Corcoran C, Crown J, O'Driscoll L. Relevance of circulating tumour cells, extracellular nucleic acids and exosomes in breast cancer. *Breast Cancer Res Treat.* 2010 123(3):613-25. [PMID: 20549336](#)

Germano S, Rani S, Kennedy S, Crown J, Clynes M, O'Driscoll L. Melanoma-associated antigen family protein-D4 (MAGED-4): clinical significance and functional relevance in breast cancer. *Breast Cancer Res. Treat* 2010;210(12):S10-11. PubMed [PMID: 21618523](#).

Madden SF, Carpenter SB, Jeffery IB, Bjorkbacka H, Fitzgerald KA, O'Neill LA, Higgins DG. Detecting microRNA activity from gene expression data. *BMC Bioinformatics*. 2010 18(11):257. [PMID: 20482775](#)

O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT. Review Article. Bioluminescent imaging: a critical tool in pre-clinical oncology research. *J Pathol*. 2010; 220 (3): 317-327. [PMID: 19967724](#).

O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. Activated Phosphoinositide 3-Kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. *Mol Can Ther* 2010; 9(6):1489-502. [PMID: 20501798](#)

O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. *Invest New Drugs*. 2010; In Press. [PMID: 20229355](#)

van der Meel R, Gallagher WM, Oliveira S, O'Connor AE, Schiffelers RM, Byrne AT. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. *Drug Discov Today*. 2010; 15 (3&4): 102-114. [PMID: 20035896](#)

Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O'Driscoll L. Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. *Br J Cancer*. 2010;102(7):1157-62. [PMID: 20234362](#)

2009 Publications

Byrne AT, O'Connor AE, Hall M, Murtagh J, O'Neill K, Curran KM, Mongrain K, Rousseau JA, Lecomte R, McGee S, Callanan JJ, O'Shea DF, Gallagher WM. Vascular-targeted photodynamic therapy with BF₂-chelated Tetraaryl-Azadipyromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. *Br J Cancer*. 2009; 101(9):1565- 1573. [PMID: 19826417](#)

Corkery B, Crown J, Roche S, O'Connor R, Tryfanopoulos D, Clynes M, O'Donovan N. Constitutive activation of Src kinase as a mechanism of resistance to dasatinib in triple negative breast cancer. *Cancer Res*. 2009; 69(24):787s

Roche S, McMahon G, Clynes M, O'Connor R. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2009; 877(31): 3982-90. [PMID: 19854117](#)